RayKnowChina Research Map
Shortlist0

Xi'an Jiaotong University

西安交通大学

Xi'anUniversity or health system

Hospitals that carry this university's name, added together, plus papers and trials that name only the university.

Research activity, not treatment quality. Not medical advice. How this works

Nasopharyngeal carcinoma

鼻咽癌
0.4%Leads under 1 in 100 of China's research papers on NPC

Led 10 of 2,375 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (23.4%).

Run this PubMed search

Open trials led
0
Research papers it led
10
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.3%
Papers led per year
2021: 2220212022: 1120222023: 1120232024: 1120242025: 002025
ThemesRadiotherapy techniqueInduction / concurrent chemotherapySide effects & quality of life

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. First Affiliated Hospital of Xi'an Jiaotong University6
  2. Second Affiliated Hospital of Xi'an Jiaotong University Counted in the group total2
  3. Affiliated Hospital of Xi'an Jiaotong University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Oesophageal squamous cell carcinoma

食管鳞状细胞癌
1.0%Leads under 1 in 100 of China's research papers on ESCC ▼ from 1.5%

Led 28 of 2,923 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (6.9%).

Run this PubMed search

Open trials led
1
Research papers it led
28
Trials it led
3
Share of China's trials
0.5%
Share of the world's papers
0.6%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 2220242025: 222025
ThemesRadiotherapyMolecular markers & genomicsImaging & AI

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. First Affiliated Hospital of Xi'an Jiaotong University12
  2. Second Affiliated Hospital of Xi'an Jiaotong University12
  3. HongHui Hospital Counted in the group total1
  4. Honghui Hospital Counted in the group total1
  5. Shaanxi Provincial Cancer Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Survival benefits of human papillomavirus 16 infection in patients with esophageal squamous cell carcinoma undergoing chemoradiotherapy: A retrospective cohort study.2024Journal of medical virology
  2. SP4 Facilitates Esophageal Squamous Cell Carcinoma Progression by Activating PHF14 Transcription and Wnt/Β-Catenin Signaling.2024Molecular cancer research : MCRFree full text
  3. An artificial neural network-based radiomics model for predicting the radiotherapy response of advanced esophageal squamous cell carcinoma patients: a multicenter study.2023Scientific reportsFree full text
  4. HPV16 Enhances Radiosensitivity in Esophageal Squamous Cell Carcinoma by Promoting De Novo Fatty Acid Synthesis and Disulfidptosis.2025Journal of medical virology
  5. Development and validation of a novel signature to predict the survival and affect the immune microenvironment of esophageal squamous cell carcinoma: epigenetic-related genes.2025Frontiers in immunologyFree full text
Trials on ClinicalTrials.gov6
  1. Adebrelimab With Famitinib and Chemotherapy as Neoadjuvant Therapy for ESCCRecruitingNCT07796113Lead sponsorPhase 2Start 2025-10
  2. SKB500 Combinations in Patients With Esophageal Squamous Cell CarcinomaRecruitingNCT07700667Study sitePhase 2Start 2026-08
  3. Value of Pleural Lavage Cytology in Resectable Esophageal Carcinoma Eastern Cooperative Thoracic Oncology Projects 2005, ECTOP-2005)RecruitingNCT05443841Study siteStart 2022-07
  4. Tislelizumab With Chemotherapy or Radiation for Neoadjuvant Therapy of Esophageal Squamous Cell Carcinoma (TINES)Status unknownNCT05603065Lead sponsorPhase 4Start 2022-10
  5. Perioperative Vs. Preoperative Chemotherapy With Surgery in the Squamous Carcinoma of EsophagusCompletedNCT01225523Lead sponsorPhase 1Start 1997-01
  6. A Study of Atezolizumab Plus Tiragolumab in Combination With Paclitaxel and Cisplatin Compared With Paclitaxel and Cisplatin as First-Line Treatment in Participants With Unresectable Locally Advanced, Unresectable Recurrent, or Metastatic Esophageal CarcinomaCompletedNCT04540211Study sitePhase 3Start 2020-10

PubMed searchClinicalTrials.gov

Hepatocellular carcinoma

肝细胞癌
1.3%Leads about 1 in 76 of China's research papers on HCC ▼ from 2.4%

Led 193 of 14,765 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (5.5%).

Run this PubMed search

Open trials led
1
Research papers it led
193
Trials it led
7
Share of China's trials
0.5%
Share of the world's papers
0.7%
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 1120242025: 332025
ThemesRecurrence & prognosisImaging, AI & early detectionImmunotherapy & targeted drugs

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. First Affiliated Hospital of Xi'an Jiaotong University122
  2. Second Affiliated Hospital of Xi'an Jiaotong University57
  3. Honghui Hospital Counted in the group total3
  4. Xi'an Children's Hospital Counted in the group total2
  5. Xi'an Jiaotong University Second Affiliated Hospital1
  6. Affiliated Children Hospital of Xi'an Jiaotong University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Matching-adjusted indirect comparison of tislelizumab plus lenvatinib versus sintilimab plus bevacizumab biosimilar as first-line treatment for unresectable hepatocellular carcinoma.2025Frontiers in immunologyRCTFree full text
  2. Trends in Hepatocellular Carcinoma Mortality Rates in the US and Projections Through 2040.2024JAMA network openFree full text
  3. Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib for Patients With Unresectable or Metastatic Hepatocellular Carcinoma.2021JAMA network openFree full text
  4. Liver tumor imaging staging: a multi-institutional study of a preoperative staging tool for hepatocellular carcinoma.2025Abdominal radiology (New York)Free full text
  5. Perioperative Changes in Serum Transaminases Levels Predicts Long-Term Survival Following Liver Resection of Hepatocellular Carcinoma.2025Annals of surgical oncology
Trials on ClinicalTrials.gov6
  1. Real-world Study Evaluating the Long-term Outcomes of Pegylated Interferon α-2b Treatment in the Families With Clusters of HBV Infection and Unfavorable Prognosis - A Prospective, Controlled, Multicenter, Cohort StudyRecruitingNCT07079150Lead sponsorStart 2025-01
  2. ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 OverexpressionRecruitingNCT07327034Study sitePhase 2Start 2025-06
  3. Comparison of ultraSound, Abbreviated MRI witH and Without HBP aS mOdalities for HCC suRveillance in patienTs With High RiskNot yet recruitingNCT07010588Study siteN/AStart 2025-06
  4. Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular CarcinomaRecruitingNCT07176650Study sitePhase 1Start 2025-11
  5. Observational Study for SIR-Spheres Therapy for the Treatment of HCC Patients in ChinaEnrolling by invitationNCT06712017Study siteStart 2024-08
  6. Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.RecruitingNCT05862337Study sitePhase 3Start 2023-05

PubMed searchClinicalTrials.gov

Stomach cancer

胃癌
1.0%Leads about 1 in 97 of China's research papers on Stomach cancer

Led 101 of 9,782 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (3.9%).

Run this PubMed search

Open trials led
1
Research papers it led
101
Trials it led
11
Share of China's trials
0.8%
Share of the world's papers
0.5%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 442025
ThemesEarly detection & endoscopySurgeryImaging & AI

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. First Affiliated Hospital of Xi'an Jiaotong University69
  2. Second Affiliated Hospital of Xi'an Jiaotong University20
  3. Honghui Hospital Counted in the group total3
  4. Xi'an Children's Hospital Counted in the group total1
  5. Third Affiliated Hospital of the School of Medicine Xi'an Jiaotong University1
  6. First Affiliated Hospital, Xi'an Jiaotong University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Preoperative Glycosylated Hemoglobin A1C Impacts Long-Term Outcomes Following Curative-Intent Resection of Nonfunctional Gastroenteropancreatic Neuroendocrine Tumors.2025Journal of surgical oncologyFree full text
  2. Construction and effect evaluation of perioperative nursing model for gastric cancer patients based on enhanced recovery after surgery (ERAS) concept.2025MedicineFree full text
  3. The mediating role of postoperative blood glucose in the relationship between body composition and overall survival in non-diabetic gastric cancer patients.2025BMC cancerFree full text
  4. Clinical outcomes and cost-effectiveness analysis of robotic and endoscopic cooperative surgery for treating gastric submucosal tumors: a longitudinal nested cohort study.2025Surgical endoscopyFree full text
  5. The staining results of early gastric cancer by indigo carmine chromoendoscopy associated with histological structure: a retrospective study.2024BMC cancerFree full text
Trials on ClinicalTrials.gov6
  1. Clinical Study of Irinotecan Liposome Combination Therapy for Advanced Gastric CancerNot yet recruitingNCT06499610Lead sponsorPhase 4Start 2024-07
  2. Radical Surgery Versus Non-Surgery in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion TherapyRecruitingNCT07789184Study sitePhase 3Start 2026-12
  3. Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.RecruitingNCT07385703Study sitePhase 3Start 2026-04
  4. Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction CancerRecruitingNCT06731478Study sitePhase 3Start 2025-02
  5. SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid TumorsRecruitingNCT06873659Study sitePhase 1Start 2025-02
  6. Feasibility of Enhanced Recovery After Surgery Without Prophylactic Abdominal Drainage Tubes After Laparoscopic Distal Gastrectomy For Gastric CancerRecruitingNCT07029269Study sitePhase 3Start 2025-06

PubMed searchClinicalTrials.gov

Retinoblastoma

视网膜母细胞瘤
2.7%Leads about 1 in 38 of China's research papers on Retinoblastoma ▲ from 0.9%

Led 8 of 301 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (12.0%).

Run this PubMed search

Open trials led
0
Research papers it led
8
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.7%
Papers led per year
2021: 1120212022: 2220222023: 1120232024: 0020242025: 112025

Over half of these papers are lab or animal studies.

PubMed searchClinicalTrials.gov

Chordoma

脊索瘤
1.9%Leads about 1 in 53 of China's research papers on Chordoma ▲ from 0.8%

Led 2 of 105 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (23.8%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.4%
Papers led per year
2021: 1120212022: 0020222023: 1120232024: 0020242025: 002025

Hospitals counted here

  1. Xi'an Children's Hospital1
  2. Second Affiliated Hospital of Xi'an Jiaotong University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Osteosarcoma

骨肉瘤
1.4%Leads about 1 in 70 of China's research papers on Osteosarcoma

Led 32 of 2,257 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.3%).

Run this PubMed search

Open trials led
0
Research papers it led
32
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.6%
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 332025

Over half of these papers are lab or animal studies.

PubMed searchClinicalTrials.gov

Gastrointestinal stromal tumour

胃肠道间质瘤
0.6%Leads under 1 in 100 of China's research papers on Gastrointestinal stromal tumour

Led 3 of 523 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (6.3%).

Run this PubMed search

Open trials led
0
Research papers it led
3
Trials it led
2
Share of China's trials
2.7%
Share of the world's papers
0.2%
Papers led per year
2021: 1120212022: 1120222023: 1120232024: 0020242025: 002025

Hospitals counted here

  1. First Affiliated Hospital of Xi'an Jiaotong University3

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Neuroblastoma

神经母细胞瘤
0.8%Leads under 1 in 100 of China's research papers on Neuroblastoma ▼ from 1.5%

Led 9 of 1,132 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.8%).

Run this PubMed search

Open trials led
0
Research papers it led
9
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 0020212022: 0020222023: 3320232024: 2220242025: 002025

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. First Affiliated Hospital of Xi'an Jiaotong University3
  2. Xi'an Children's Hospital3
  3. Hong Hui Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Multiple myeloma

多发性骨髓瘤
1.7%Leads about 1 in 60 of China's research papers on Myeloma ▼ from 3.6%

Led 28 of 1,676 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.8%).

Run this PubMed search

Open trials led
0
Research papers it led
28
Trials it led
4
Share of China's trials
0.8%
Share of the world's papers
0.3%
Papers led per year
2021: 0020212022: 2220222023: 1120232024: 1120242025: 112025
ThemesDiagnosis, MRD & riskCAR-T & cell therapyRelapse & resistance

Hospitals counted here

  1. Second Affiliated Hospital of Xi'an Jiaotong University17
  2. First Affiliated Hospital of Xi'an Jiaotong University8
  3. Xi'an Jiaotong University Second Affiliated Hospital1
  4. Honghui Hospital Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Efficacy and safety of anti-CD38 monoclonal antibodies in patients with newly diagnosed multiple myeloma: an updated systematic review and meta-analysis based on randomized controlled trials.2025Leukemia & lymphoma
  2. Outcomes in patients with multiple myeloma receiving salvage treatment after BCMA-specific CAR-T therapy: A retrospective analysis of LEGEND-2.2024British journal of haematology
  3. A comprehensive analysis of coagulopathy during anti-B cell maturation antigen chimeric antigen receptor-T therapy in multiple myeloma, a retrospective study based on LEGEND-2.2023Hematological oncology
  4. Five-year remission without disease progression in a patient with relapsed/refractory multiple myeloma with extramedullary disease treated with LCAR-B38M chimeric antigen receptor T cells in the LEGEND-2 study: a case re2022Journal of medical case reportsFree full text
  5. Four-year follow-up of LCAR-B38M in relapsed or refractory multiple myeloma: a phase 1, single-arm, open-label, multicenter study in China (LEGEND-2).2022Journal of hematology & oncologyFree full text
Trials on ClinicalTrials.gov6
  1. A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple MyelomaRecruitingNCT07518186Study sitePhase 3Start 2026-05
  2. To Evaluate the Safety of SG2918 in Patients With Relapsed/Refractory Multiple MyelomaRecruitingNCT07454187Study sitePhase 1/Phase 2Start 2026-04
  3. A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple MyelomaRecruitingNCT07258511Study sitePhase 3Start 2026-02
  4. Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple MyelomaNot yet recruitingNCT07569757Study sitePhase 3Start 2026-06
  5. A Study of GR1803 Injection in Combination With Anti-CD38 Monoclonal Antibody for the Treatment of Participants With Multiple MyelomaNot yet recruitingNCT07090954Study sitePhase 1/Phase 2Start 2025-08
  6. A Clinical Study Assessing the Subcutaneous Formulation of TQB2934 for Injection in Subjects With Malignant Plasma Cell TumorsRecruitingNCT07179679Study sitePhase 1Start 2025-12

PubMed searchClinicalTrials.gov

B-cell acute lymphoblastic leukaemia (B-ALL)

B 细胞急性淋巴细胞白血病
0.0%Leads none of China's research papers on B-ALL

Led 0 of 225 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.9%).

Run this PubMed search

Open trials led
0
Research papers it led
0
Trials it led
1
Share of China's trials
0.4%
Share of the world's papers
0.0%

PubMed searchClinicalTrials.gov

Aplastic anaemia

再生障碍性贫血
0.2%Leads under 1 in 100 of China's research papers on Aplastic anaemia ▼ from 1.2%

Led 1 of 412 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (17.2%).

Run this PubMed search

Open trials led
0
Research papers it led
1
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.06%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025
ThemesStem cell transplant

Hospitals counted here

  1. First Affiliated Hospital of Xi'an Jiaotong University Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Haemophilia A

血友病 A
0.7%Leads under 1 in 100 of China's research papers on Haemophilia A

Led 2 of 272 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (15.8%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.07%
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 1120242025: 002025

Hospitals counted here

  1. Xi'an Central Hospital, Xi'an Jiaotong University1
  2. First Affiliated Hospital of Xi'an Jiaotong University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Biliary atresia

胆道闭锁
1.9%Leads about 1 in 53 of China's research papers on Biliary atresia

Led 4 of 214 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (9.8%).

Run this PubMed search

Open trials led
0
Research papers it led
4
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.5%
Papers led per year
2021: 1120212022: 2220222023: 0020232024: 0020242025: 112025
ThemesKasai operationComplications after surgeryDisease mechanisms

Hospitals counted here

  1. Xi'an Children's Hospital3
  2. First Affiliated Hospital of Xi'an Jiaotong University Counted in the group total1
  3. Second Affiliated Hospital of Xi'an Jiaotong University Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Takayasu arteritis

大动脉炎
1.1%Leads about 1 in 93 of China's research papers on Takayasu arteritis

Led 2 of 187 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (24.6%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 112025

Hospitals counted here

  1. First Affiliated Hospital of Xi'an Jiaotong University2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Idiopathic pulmonary fibrosis

特发性肺纤维化
1.5%Leads about 1 in 66 of China's research papers on Idiopathic pulmonary fibrosis New since 2021

Led 15 of 989 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.3%).

Run this PubMed search

Open trials led
0
Research papers it led
15
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.4%
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 442025

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. First Affiliated Hospital of Xi'an Jiaotong University8
  2. Second Affiliated Hospital of Xi'an Jiaotong University4
  3. Xi'an Children's Hospital1
  4. Honghui Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Magnetic resonance imaging of focal organizing pneumonia: differential diagnosis with peripheral lung carcinoma.2025Acta radiologica (Stockholm, Sweden : 1987)
  2. Galectin-9 regulates follicular helper T cells to inhibit humoral autoimmunity-induced pulmonary fibrosis.2021Biochemical and biophysical research communications
  3. Exercise improves pulmonary fibrosis and neurological symptoms via S100A12 inhibition.2025Frontiers in immunology
  4. PIEZO1 mediates periostin+ myofibroblast activation and pulmonary fibrosis in mice.2025The Journal of clinical investigation
  5. circ0066187 promotes pulmonary fibrogenesis through targeting STAT3-mediated metabolism signal pathway.2025Cellular and molecular life sciences : CMLS
Trials on ClinicalTrials.gov5
  1. Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)RecruitingNCT07687459Study sitePhase 3Start 2026-09
  2. A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With NerandomilastActive, not recruitingNCT06238622Study sitePhase 3Start 2024-09
  3. A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)CompletedNCT05321069Study sitePhase 3Start 2022-10
  4. Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)TerminatedNCT04419558Study sitePhase 3Start 2020-09
  5. Zephyrus I: Evaluation of Efficacy and Safety of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)TerminatedNCT03955146Study sitePhase 3Start 2019-06

PubMed searchClinicalTrials.gov

Amyotrophic lateral sclerosis

肌萎缩侧索硬化症
0.5%Leads under 1 in 100 of China's research papers on Amyotrophic lateral sclerosis ▼ from 2.3%

Led 4 of 779 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.3%).

Run this PubMed search

Open trials led
0
Research papers it led
4
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.06%
Papers led per year
2021: 1120212022: 1120222023: 2220232024: 0020242025: 002025

Hospitals counted here

  1. First Affiliated Hospital of Xi'an Jiaotong University3
  2. Honghui Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Spinal muscular atrophy

脊髓性肌萎缩症
7.3%Leads about 1 in 14 of China's research papers on Spinal muscular atrophy New since 2021

Led 4 of 55 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (29.1%).

Run this PubMed search

Open trials led
0
Research papers it led
4
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.7%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 3320242025: 112025

Hospitals counted here

  1. Second Affiliated Hospital of Xi'an Jiaotong University4

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Fabry disease

法布雷病
1.4%Leads about 1 in 73 of China's research papers on Fabry disease New since 2021

Led 1 of 73 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (12.3%).

Run this PubMed search

Open trials led
0
Research papers it led
1
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.1%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

Hospitals counted here

  1. Second Affiliated Hospital of Xi'an Jiaotong University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Pompe disease

庞贝病
6.7%Leads about 1 in 15 of China's research papers on Pompe disease

Led 2 of 30 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (6.7%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.5%
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 1120242025: 002025

Hospitals counted here

  1. Xi'an Children's Hospital2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Behçet disease

白塞病
0.8%Leads under 1 in 100 of China's research papers on Behçet disease

Led 2 of 245 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (22.9%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.1%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 1120242025: 002025

Hospitals counted here

  1. Second Affiliated Hospital of Xi'an Jiaotong University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

IgA nephropathy

IgA 肾病
1.2%Leads about 1 in 82 of China's research papers on IgA nephropathy ▼ from 3.2%

Led 9 of 736 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (9.4%).

Run this PubMed search

Open trials led
0
Research papers it led
9
Trials it led
1
Share of China's trials
0.9%
Share of the world's papers
0.5%
Papers led per year
2021: 0020212022: 3320222023: 0020232024: 2220242025: 002025

Hospitals counted here

  1. First Affiliated Hospital of Xi'an Jiaotong University6
  2. Second Affiliated Hospital of Xi'an Jiaotong University2
  3. Honghui Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Primary biliary cholangitis

原发性胆汁性胆管炎
1.3%Leads about 1 in 75 of China's research papers on Primary biliary cholangitis New since 2021

Led 4 of 300 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (12.0%).

Run this PubMed search

Open trials led
0
Research papers it led
4
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.4%
Papers led per year
2021: 1120212022: 2220222023: 0020232024: 1120242025: 002025

Hospitals counted here

  1. Second Affiliated Hospital of Xi'an Jiaotong University2
  2. First Affiliated Hospital of Xi'an Jiaotong University2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Primary sclerosing cholangitis

原发性硬化性胆管炎
3.0%Leads about 1 in 33 of China's research papers on Primary sclerosing cholangitis ▲ from 2.0%

Led 3 of 100 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (7.0%).

Run this PubMed search

Open trials led
0
Research papers it led
3
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.3%
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 2220242025: 002025

Hospitals counted here

  1. Second Affiliated Hospital of Xi'an Jiaotong University2
  2. Honghui Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Hirschsprung disease

先天性巨结肠
3.7%Leads about 1 in 27 of China's research papers on Hirschsprung disease ▼ from 5.8%

Led 6 of 161 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (13.0%).

Run this PubMed search

Open trials led
0
Research papers it led
6
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.8%
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 1120242025: 112025

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. Second Affiliated Hospital of Xi'an Jiaotong University5
  2. Xi'an Children's Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov